Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27699140 | 0.98 | KMT2A (0.53) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL27545486 | 0.88 | CA2 (0.59) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL9365762 | 0.80 | CA2 (0.57) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL9451309 | 0.78 | CA2 (0.55) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL323791 | 0.78 | CA1 (0.58) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL10736241 | 0.77 | KMT2A (0.60) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL20768536 | 0.77 | KMT2A (0.60) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL29171358 | 0.77 | KMT2A (0.55) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL27390987 | 0.77 | KMT2A (0.55) | KMT2AMEN1CA2CA1CA9 | |
| SCHEMBL9451377 | 0.77 | KMT2A (0.50) | KMT2AMEN1CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5025031-A | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants | A. H. ROBINS CO., INC. (US) | 1991-06-18 | — | — | US | claimed |
| EP-0403185-A2 | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-12-19 | — | — | EP | claimed |
| CN-104725856-B | Conductive composition and the electric conductor and solid electrolytic capacitor of above-mentioned conductive composition are used | 三菱丽阳株式会社 | 2017-06-09 | — | — | CN | disclosed |
| US-7335687-B2 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | ACKERMANN JEAN (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6858651-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-02-22 | — | — | US | disclosed |
| CN-1119457-C | Method for improving wet strength of paper | KIMBERLY CLARK CO (US) | 2003-08-27 | — | — | CN | disclosed |
| CN-1341571-A | Aminosulfonic acid series high-effective water-reducing agent and its preparation method | HUA NAN UNIVERSITY OF SCIENCE (CN) | 2002-03-27 | — | — | CN | disclosed |
| CN-1292838-A | Method for improving wet strength of paper | KIMBERLY CLARK CO (US) | 2001-04-25 | — | — | CN | disclosed |
| US-5273993-A | Antiarthritic agents; osteoporosis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-12-28 | — | — | US | disclosed |
| US-5194446-A | Antiarthritic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-16 | — | — | US | disclosed |
| US-5192785-A | Sulfamates as antiglaucoma agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-09 | — | — | US | disclosed |
| US-5025031-A | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants | A. H. ROBINS CO., INC. (US) | 1991-06-18 | — | — | US | disclosed |
| EP-0403185-A2 | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | KMT2A 3998/4885MEN1 429/4885CA2 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.